|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,984.00 GBX | +0.72% |
|
+2.57% | +4.85% |
| 06-02 | ASTRAZENECA : Buy rating from JP Morgan | ZD |
| 06-02 | UK's FTSE 100 closes around flat as staples, healthcare losses eclipse energy gains | RE |
| Capitalization | 229B 199B 188B 169B 313B 19,575B 351B 2,188B 847B 8,963B 859B 841B 33,134B | P/E ratio 2025 * |
23.1x | P/E ratio 2026 * | 19.2x |
|---|---|---|---|---|---|
| Enterprise value | 249B 217B 204B 184B 341B 21,307B 383B 2,381B 922B 9,756B 935B 916B 36,065B | EV / Sales 2025 * |
4.31x | EV / Sales 2026 * | 3.95x |
| Free-Float |
96.62% | Yield 2025 * |
2.18% | Yield 2026 * | 2.29% |
More valuation ratios
* Estimated data
More news
Last Transcript: AstraZeneca PLC
More press releases
| 1 day | +0.24% | ||
| 1 week | +2.22% | ||
| Current month | +2.03% | ||
| 1 month | +6.48% | ||
| 3 months | -6.11% | ||
| 6 months | +3.50% | ||
| Current year | +4.49% |
| 1 week | 10,674 |  | 10,982 |
| 1 month | 9,932 | | 10,982 |
| Current year | 9,573.5 | | 12,208 |
| 1 year | 9,573.5 | | 13,388 |
| 3 years | 9,399 | | 13,388 |
| 5 years | 6,736 | | 13,388 |
| 10 years | 3,680 | | 13,388 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 65 | 30/09/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 31/07/2021 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 31/07/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 05/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 65 | 30/09/2012 |
Philip Broadley
BRD | Director/Board Member | 64 | 26/04/2017 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 8.29% | 57 M€ | +11.94% | - | |
| 5.39% | 200 M€ | -0.78% | - | |
| 5.17% | 21 M€ | +0.90% | - | |
| 4.89% | 1,138 M€ | +0.94% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.24% | +2.22% | -12.26% | +11.87% | 229B | ||
| +0.18% | +5.58% | -6.61% | +172.25% | 726B | ||
| -0.76% | +1.33% | +5.79% | -10.02% | 374B | ||
| -0.08% | +5.33% | -47.81% | +34.12% | 353B | ||
| +1.06% | +2.22% | +14.19% | +33.73% | 338B | ||
| +0.07% | +0.86% | +10.88% | -12.69% | 264B | ||
| +0.39% | +0.76% | +2.89% | +17.66% | 232B | ||
| -1.27% | +2.62% | -39.08% | -7.87% | 202B | ||
| -0.55% | +1.67% | -2.96% | +21.58% | 157B | ||
| +0.74% | +4.66% | -12.67% | -51.01% | 139B | ||
| Average | +0.13% | +3.20% | -8.76% | +20.96% | 301.39B | |
| Weighted average by Cap. | +0.20% | +3.64% | -7.99% | +47.42% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 57.83B 50.36B 47.41B 42.69B 79.05B 4,942B 88.73B 552B 214B 2,263B 217B 212B 8,365B | 61.18B 53.28B 50.15B 45.17B 83.63B 5,228B 93.87B 584B 226B 2,394B 229B 225B 8,850B |
| Net income | 9.92B 8.64B 8.13B 7.32B 13.56B 848B 15.22B 94.74B 36.69B 388B 37.2B 36.43B 1,435B | 11.95B 10.4B 9.79B 8.82B 16.33B 1,021B 18.33B 114B 44.19B 467B 44.81B 43.88B 1,728B |
| Net Debt | 20.26B 17.65B 16.61B 14.96B 27.7B 1,732B 31.09B 194B 74.95B 793B 76B 74.42B 2,931B | 12.88B 11.21B 10.56B 9.51B 17.6B 1,101B 19.76B 123B 47.63B 504B 48.3B 47.3B 1,863B |
More financial data
* Estimated data
Employees
94,300
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/25 | 10,980.00 p | +0.68% | 145,346 |
| 11/06/25 | 10,906.00 p | +0.31% | 1,482,294 |
| 10/06/25 | 10,872.00 p | +0.93% | 910,150 |
| 09/06/25 | 10,772.00 p | -0.09% | 629,958 |
| 06/06/25 | 10,782.00 p | +0.77% | 1,035,006 |
Delayed Quote London S.E., June 12, 2025 at 09:33 am
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
147.72USD
Average target price
179.12USD
Spread / Average Target
+21.25%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition